Evidence map›Paper›PMID 34569406›Full record

ArticleDrug delivery2021

A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer.

Zhiyuan Zhang, Tianhao Su, Yanjing Han, Zeran Yang, Jian Wei, Long Jin, Haining Fan

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Advances in the Use of Metformin for Liver Disease.Current medicinal chemistry · 2025
    Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Zhiyuan ZhangDepartment of Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Tianhao SuDepartment of Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Yanjing HanDepartment of Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Zeran YangDepartment of Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Jian WeiDepartment of Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Long JinDepartment of Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Haining FanDepartment of Hepatopancreatobiliary Surgery, Affiliated Hospital of Qinghai University, Xining, China.
Beijing Friendship Hospital · CNCapital Medical University · CNQinghai University Affiliated Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is widespread cancer with a high degree of morbidity and mortality in individuals worldwide and a serious concern for its resistance to present chemotherapy drugs. In this investigation, the combination of cisplatin (CPT) and metformin (MET) to kill the HepG2 and caco-2 cells was developed into a new pH-responding magnetic nanocomposite based on reduced graphene oxide. Polyhydroxyethyl methacrylic (PHEA) was then linked employing grafting from approach to the reduced graphene oxide by ATRP polymerization (Fe

Indexed as

AnimalsAntineoplastic AgentsApoptosisCaco-2 CellsCarcinoma, HepatocellularCell SurvivalChemistry, PharmaceuticalCisplatinDrug CarriersDrug LiberationGraphiteHep G2 CellsHumansLiver NeoplasmsMagnetic Iron Oxide NanoparticlesMaleAntineoplastic AgentsCisplatinDrug Carriersgraphene oxideGraphiteMetforminpoly(2-hydroxyethyl acrylate)Polyhydroxyethyl MethacrylateReactive Oxygen SpeciesapoptosisCombination drugsgraphenehepatocellular carcinomain vivo animal model

Identifiers

PMID34569406
PMCPMC8477966
OpenAlexW3204868047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.